Clinical Updates on the Treament of Patients with Hodgkin Lymphoma

Adcetris® in the BrECADD regimen is recommended as the standard of care for adults aged ≤60 years with newly diagnosed classical Hodgkin lymphoma (cHL) in advanced stages. [1] The recommendation is based on the favorable results from the HD21 phase 3 study*, comparing BrECADD vs. eBEACOPP as first line treatment in patients with advanced CD30+ cHL. [2] PD Dr. med. Paul J Bröckelmann, member of the German Hodgkin Study Group (GHSG), provides further insights on this topic.
 

Image

* The HD21 study is a randomized, multicenter, open-label phase 3 study involving 1500 patients with newly diagnosed, advanced-stage, cHL from 233 study centers in 9 countries. The study compared BrECADD vs. eBEACOPP [2]


BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; cHL: classical Hodgkin lymphoma; eBEACOPP: escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone


Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.


Adcetris® Information for healthcare professionals, www.swissmedicinfo-pro.ch

C-APROM/CH/ADCE/0100 11/2025

Further information

  • 1. Eyre TA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025:S0923-7534(25)00911-1.

  • 2. Borchmann P, et al. Assessing the e_icacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024;404(10450):341–352.